Genetics and pathology of pancreatic cancer

HPB

Volumn 8, Issue 5, 2006, Pages 324-336

  Winter, Jordan M ^a   Maitra, Anirban ^a   Yeo, Charles J ^b  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Genes; Genetics; Pancreatic adenocarcinoma; Tumor suppressor genes

Indexed keywords

CARCINOGENESIS; CHROMOSOME ABERRATION; CHROMOSOME LOSS; EPIGENETICS; FAMILIAL CANCER; GENE MUTATION; GENE OVEREXPRESSION; GENE SILENCING; GENOME ANALYSIS; HUMAN; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; MICROSATELLITE INSTABILITY; MOLECULAR GENETICS; NONHUMAN; ONCOGENE; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 33749185439     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1080/13651820600804203     Document Type: Review

References (109)

1. Jemal, A and Murray, T and Ward, E and Samuels, A and Tiwari, RC and Ghafoor, A and (2005) Cancer statistics, 2005 CA Cancer J Clin, 55, pp. 10-30.
2. RiesLAG, EisnerMP, KosaryCL, HankeyBF, MillerBA, CleggL, SEER Cancer Statistics Review, 1975-2000. BethesdaMD: National Cancer Institute, 2003. http://seer.cancer.gov/csr/1975_2000
3. Parkin, DM and Bray, F and Ferlay, J and Pisani, P. (2001) Estimating the world cancer burden: Globocan 2000 Int J Cancer, 94, pp. 153-6.
4. Hansel, DE and Kern, SE and Hruban, RH. (2003) Molecular pathogenesis of pancreatic cancer Annu Rev Genomics Hum Genet, 4, pp. 237-56.
5. Trask, B. (2002) Human cytogenetics: 46 chromosomes, 46 years and counting Nat Rev Genet, 3, pp. 769-78.
6. Kricka, LJ and Fortina, P. (2001) Microarray technology and applications: An all-language literature survey including books and patents Clin Chem, 47, pp. 1479-82.
7. CoeB, AntlerB. Spot your genes - an overview of the microarray BioTeach http://www.bioteach.ubc.ca/MolecularBiology/microarray/ [accessed 9 January 2005].
8. Albertson, DG and Pinkel, D. (2003) Genomic microarrays in human genetic disease and cancer Hum Mol Genet, 12, pp. 145-52.
9. Malkhosyan, S and Yasuda, J and Soto, JL and Sekiya, T and Yokota, J and Perucho, M. (1998) Molecular karyotype (amplotype) of metastatic colorectal cancer by unbiased arbitrarily primed PCR DNA fingerprinting Proc Natl Acad Sci U S A, 95, pp. 10170-5.
10. Iacobuzio-Donahue, CA and van der Heijden, MS and Baumgartner, MR and Troup, WJ and Romm, JM and Doheny, K and (2004) Large-scale allelotype of pancreaticobiliary carcinoma provides quantitative estimates of genome-wide allelic loss Cancer Res, 64, pp. 871-5.
11. Novak, U and Oppliger Leibundgut, E and Hager, J and Muhlematter, D and Jotterand, M and Besse, C and (2002) A high-resolution allelotype of B-cell chronic lymphocytic leukemia (B-CLL) Blood, 100, pp. 1787-94.
12. Mahlamaki, EH and Hoglund, M and Gorunova, L and Karhu, R and Dawiskiba, S and Andren-Sandberg, A and (1997) Comparative genomic hybridization reveals frequent gains of 20q, 8q, 11q, 12p, and 17q, and losses of 18q, 9p, and 15q in pancreatic cancer Genes Chromosomes Cancer, 20, pp. 383-91.
13. Curtis, LJ and Li, Y and Gerbault-Seureau, M and Kuick, R and Dutrillaux, AM and Goubin, G and (1998) Amplification of DNA sequences from chromosome 19q13.1 in human pancreatic cell lines Genomics, 53, pp. 42-55.
14. Schleger, C and Arens, N and Zentgraf, H and Bleyl, U and Verbeke, C. (2000) Identification of frequent chromosomal aberrations in ductal adenocarcinoma of the pancreas by comparative genomic hybridization (CGH) J Pathol, 191, pp. 27-32.
15. Ghadimi, BM and Schrock, E and Walker, RL and Wangsa, D and Jauho, A and Meltzer, PS and (1999) Specific chromosomal aberrations and amplification of the AIB1 nuclear receptor coactivator gene in pancreatic carcinomas Am J Pathol, 154, pp. 525-36.
16. Wilentz, RE and Goggins, M and Redston, M and Marcus, VA and Adsay, NV and Sohn, TA and (2000) Genetic, immunohistochemical, and clinical features of medullary carcinoma of the pancreas: A newly described and characterized entity Am J Pathol, 156, pp. 1641-51.
17. BolandCR. Hereditary nonpolyposis colorectal cancerIn:VOgelsteinB, KinzlerKW. The genetic basis of human cancer. New York: McGraw-Hill, 1998:307-21.
18. Feinberg, AP. (2004) The epigenetics of cancer etiology Semin Cancer Biol, 14, pp. 427-32.
19. Ueki, T and Toyota, M and Sohn, T and Yeo, CJ and Issa, JP and Hruban, RH and (2000) Hypermethylation of multiple genes in pancreatic adenocarcinoma Cancer Res, 60, pp. 1835-9.
20. Ueki, T and Walter, KM and Skinner, H and Jaffee, E and Hruban, RH and Goggins, M. (2002) Aberrant CpG island methylation in cancer cell lines arises in the primary cancers from which they were derived Oncogene, 21, pp. 2114-17.
21. Sohn, TA. (2002) The molecular genetics of pancreatic ductal carcinoma Minerva Chir, 57, pp. 561-74.
22. Caldas, C and Hahn, SA and da Costa, LT and Redston, MS and Schutte, M and Seymour, AB and (1994) Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma Nat Genet, 8, pp. 27-32.
23. Schutte, M and Hruban, RH and Geradts, J and Maynard, R and Hilgers, W and Rabindran, SK and (1997) Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas Cancer Res, 57, pp. 3126-30.
24. Morgan, D.(2002) The cell cycle and programmed cell death. In Molecular biology of the cell. (pp. 1007-8). New York: Garland Science.
25. Redston, MS and Caldas, C and Seymour, AB and Hruban, RH and da Costa, L and Yeo, CJ and (1994) p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions Cancer Res, 54, pp. 3025-33.
26. Pellegata, NS and Sessa, F and Renault, B and Bonato, M and Leone, BE and Solcia, E and (1994) K-ras and p53 gene mutations in pancreatic cancer: Ductal and nonductal tumors progress through different genetic lesions Cancer Res, 54, pp. 1556-60.
27. Taylor, WR and Stark, GR. (2005) Regulation of the G2/M transition by p53 Oncogene, 20, pp. 1803-15.
28. Hahn, SA and Schutte, M and Hoque, AT and Moskaluk, CA and da Costa, LT and Rozenblum, E and (1996) DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1 Science, 271, pp. 350-3.
29. Yoo, J and Ghiassi, M and Jirmanova, L and Balliet, AG and Hoffman, B and Fornace, AJ, Jr and (2003) Transforming growth factor-beta-induced apoptosis is mediated by Smad-dependent expression of GADD45b through p38 activation J Biol Chem, 278, pp. 43001-7.
30. Goggins, M and Shekher, M and Turnacioglu, K and Yeo, CJ and Hruban, RH and Kern, SE. (1998) Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas Cancer Res, 58, pp. 5329-32.
31. Hempen, PM and Zhang, L and Bansal, RK and Iacobuzio-Donahue, CA and Murphy, KM and Maitra, A and (2003) Evidence of selection for clones having genetic inactivation of the activin A type II receptor (ACVR2) gene in gastrointestinal cancers Cancer Res, 63, pp. 994-9.
32. Su, GH and Hilgers, W and Shekher, MC and Tang, DJ and Yeo, CJ and Hruban, RH and (1998) Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor suppressor gene Cancer Res, 58, pp. 2339-42.
33. Su, GH and Hruban, RH and Bansal, RK and Bova, GS and Tang, DJ and Shekher, MC and (1999) Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers Am J Pathol, 154, pp. 1835-40.
34. Spicer, J and Ashworth, A. (2004) LKB1 kinase: Master and commander of metabolism and polarity Curr Biol, 14, pp. R383-5.
35. Goggins, M and Schutte, M and Lu, J and Moskaluk, CA and Weinstein, CL and Petersen, GM and (1996) Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas Cancer Res, 56, pp. 5360-4.
36. Murphy, KM and Brune, KA and Griffin, C and Sollenberger, JE and Petersen, GM and Bansal, R and (2002) Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17% Cancer Res, 62, pp. 3789-93.
37. van der Heijden, MS and Yeo, CJ and Hruban, RH and Kern, SE. (2003) Fanconi anemia gene mutations in young-onset pancreatic cancer Cancer Res, 63, pp. 2585-8.
38. Almoguera, C and Shibata, D and Forrester, K and Martin, J and Arnheim, N and Perucho, M. (1988) Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes Cell, 53, pp. 549-54.
39. Hruban, RH and van Mansfeld, AD and Offerhaus, GJ and van Weering, DH and Allison, DC and Goodman, SN and (1993) K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization Am J Pathol, 143, pp. 545-54.
40. Smit, VT and Boot, AJ and Smits, AM and Fleuren, GJ and Cornelisse, CJ and Bos, JL. (1988) KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas Nucleic Acids Res, 16, pp. 7773-82.
41. Kalthoff, H and Schmiegel, W and Roeder, C and Kasche, D and Schmidt, A and Lauer, G and (1993) p53 and K-RAS alterations in pancreatic epithelial cell lesions Oncogene, 8, pp. 289-98.
42. Calhoun, ES and Jones, JB and Ashfaq, R and Adsay, V and Baker, SJ and Valentine, V and (2003) BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: Potential therapeutic targets Am J Pathol, 163, pp. 1255-60.
43. Polyak, K and Riggins, GJ. (2001) Gene discovery using the serial analysis of gene expression technique: Implications for cancer research J Clin Oncol, 19, pp. 2948-58.
44. Guo, QM. (2003) DNA microarray and cancer Curr Opin Oncol, 15, pp. 36-43.
45. Iacobuzio-Donahue, CA and Ashfaq, R and Maitra, A and Adsay, NV and Shen-Ong, GL and Berg, K and (2003) Highly expressed genes in pancreatic ductal adenocarcinomas: A comprehensive characterization and comparison of the transcription profiles obtained from three major technologies Cancer Res, 63, pp. 8614-22.
46. Ryu, B and Jones, J and Blades, NJ and Parmigiani, G and Hollingsworth, MA and Hruban, RH and (2002) Relationships and differentially expressed genes among pancreatic cancers examined by large-scale serial analysis of gene expression Cancer Res, 62, pp. 819-26.
47. Argani, P and Rosty, C and Reiter, RE and Wilentz, RE and Murugesan, SR and Leach, SD and (2001) Discovery of new markers of cancer through serial analysis of gene expression: Prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma Cancer Res, 61, pp. 4320-4.
48. Argani, P and Iacobuzio-Donahue, C and Ryu, B and Rosty, C and Goggins, M and Wilentz, RE and (2001) Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: Identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE) Clin Cancer Res, 7, pp. 3862-8.
49. Iacobuzio-Donahue, CA and Maitra, A and Shen-Ong, GL and van Heek, T and Ashfaq, R and Meyer, R and (2002) Discovery of novel tumor markers of pancreatic cancer using global gene expression technology Am J Pathol, 160, pp. 1239-49.
50. Han, H and Bearss, DJ and Browne, LW and Calaluce, R and Nagle, RB and Von Hoff, DD. (2002) Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray Cancer Res, 62, pp. 2890-6.
51. Crnogorac-Jurcevic, T and Missiaglia, E and Blaveri, E and Gangeswaran, R and Jones, M and Terris, B and (2003) Molecular alterations in pancreatic carcinoma: Expression profiling shows that dysregulated expression of S100 genes is highly prevalent J Pathol, 201, pp. 63-74.
52. Crnogorac-Jurcevic, T and Efthimiou, E and Nielsen, T and Loader, J and Terris, B and Stamp, G and (2002) Expression profiling of microdissected pancreatic adenocarcinomas Oncogene, 21, pp. 4587-94.
53. Iacobuzio-Donahue, CA and Maitra, A and Olsen, M and Lowe, AW and van Heek, NT and Rosty, C and (2003) Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays Am J Pathol, 162, pp. 1151-62.
54. Real, FX and Vila, MR and Skoudy, A and Ramaekers, FC and Corominas, JM. (1993) Intermediate filaments as differentiation markers of exocrine pancreas. II. Expression of cytokeratins of complex and stratified epithelia in normal pancreas and in pancreas cancer Int J Cancer, 54, pp. 720-7.
55. Sinha, P and Hutter, G and Kottgen, E and Dietel, M and Schadendorf, D and Lage, H. (1999) Increased expression of epidermal fatty acid binding protein, cofilin, and 14-3-3-sigma (stratifin) detected by two-dimensional gel electrophoresis, mass spectrometry and microsequencing of drug-resistant human adenocarcinoma of the pancreas Electrophoresis, 20, pp. 2952-60.
56. Elsasser, HP and MacDonald, R and Dienst, M and Kern, HF. (1993) Characterization of a transglutaminase expressed in human pancreatic adenocarcinoma cells Eur J Cell Biol, 61, pp. 321-8.
57. HrubanRH, PetersenGM, Goggins, M, TersmetteAC, OfferhausGJ, FalatkoF, Familial pancreatic cancer Ann Oncol 1999;10:569-573. http://pathology2.jhu.edu/pancreas/nfptr.cfm
58. Tersmette, AC and Petersen, GM and Offerhaus, GJ and Falatko, FC and Brune, KA and Goggins, M and (2001) Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer Clin Cancer Res, 7, pp. 738-44.
59. Bartsch, DK and Kress, R and Sina-Frey, M and Grutzmann, R and Gerdes, B and Pilarsky, C and (2004) Prevalence of familial pancreatic cancer in Germany Int J Cancer, 110, pp. 902-6.
60. Rieder, H and Bartsch, D. (2004) Familial pancreatic cancer Fam Cancer, 3, pp. 69-74.
61. Eberle, MA and Pfutzer, R and Pogue-Geile, KL and Bronner, MP and Crispin, D and Kimmey, MB and (2002) A new susceptibility locus for autosomal dominant pancreatic cancer maps to chromosome 4q32-34 Am J Hum Genet, 70, pp. 1044-8.
62. Rulyak, SJ and Brentnall, TA. (2001) Inherited pancreatic cancer: surveillance and treatment strategies for affected families Pancreatology, 1, pp. 477-85.
63. Canto, MI and Goggins, M and Yeo, CJ and Griffin, C and Axilbund, JE and Brune, K and (2004) Screening for pancreatic neoplasia in high-risk individuals: An EUS-based approach Clin Gastroenterol Hepatol, 2, pp. 606-21.
64. Lynch, HT and Deters, CA and Lynch, JF and Brand, RE. (2004) Familial pancreatic carcinoma in Jews Fam Cancer, 3, pp. 233-40.
65. Salovaara, R and Loukola, A and Kristo, P and Kaariainen, H and Ahtola, H and Eskelinen, M and (2000) Population-based molecular detection of hereditary nonpolyposis colorectal cancer J Clin Oncol, 18, pp. 2193-200.
66. Peltomaki, P and Gao, X and Mecklin, JP. (2001) Genotype and phenotype in hereditary nonpolyposis colon cancer: A study of families with different vs. shared predisposing mutations Fam Cancer, 1, pp. 9-15.
67. UlrichCD. Growth factors, receptors, and molecular alterations in pancreatic cancer. Putting it all together Med Clin North Am 2000;84:697-705, xi-xii.
68. Watson, P and Lynch, HT. (2001) Cancer risk in mismatch repair gene mutation carriers Fam Cancer, 1, pp. 57-60.
69. Giardiello, FM and Welsh, SB and Hamilton, SR and Offerhaus, GJ and Gittelsohn, AM and Booker, SV and (1987) Increased risk of cancer in the Peutz-Jeghers syndrome N Engl J Med, 316, pp. 1511-14.
70. Vasen, HF and Gruis, NA and Frants, RR and van Der Velden, PA and Hille, ET and Bergman, W. (2000) Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden) Int J Cancer, 87, pp. 809-11.
71. Thompson, D and Easton, DF. (2002) Breast Cancer Linkage Consortium. Cancer incidence in BRCA1 mutation carriers J Natl Cancer Inst, 94, pp. 1358-65.
72. Figer, A and Irmin, L and Geva, R and Flex, D and Sulkes, J and Sulkes, A and (2001) The rate of the 6174delT founder Jewish mutation in BRCA2 in patients with non-colonic gastrointestinal tract tumours in Israel Br J Cancer, 84, pp. 478-81.
73. Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 1999;91:1310-16.
74. Ozcelik, H and Schmocker, B and Di Nicola, N and Shi, XH and Langer, B and Moore, M and (1997) Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients Nat Genet, 16, pp. 17-18.
75. Whitcomb, DC and Gorry, MC and Preston, RA and Furey, W and Sossenheimer, MJ and Ulrich, CD and (1996) Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene Nat Genet, 14, pp. 141-5.
76. Witt, H and Luck, W and Hennies, HC and Classen, M and Kage, A and Lass, U and (2000) Mutations in the gene encoding the serine protease inhibitor, Kazal type 1 are associated with chronic pancreatitis Nat Genet, 25, pp. 213-16.
77. Lowenfels, AB and Maisonneuve, P and DiMagno, EP and Elitsur, Y and Gates, LK, Jr and Perrault, J and (1997) Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group J Natl Cancer Inst, 89, pp. 442-6.
78. Lowenfels, AB and Maisonneuve, P. (2002) Epidemiologic and etiologic factors of pancreatic cancer Hematol Oncol Clin North Am, 16, pp. 1-16.
79. Meszoely, IM and Means, AL and Scoggins, CR and Leach, SD. (2001) Developmental aspects of early pancreatic cancer Cancer J, 7, pp. 242-50.
80. Sessa, F and Bonato, M and Frigerio, B and Capella, C and Solcia, E and Prat, M and (1990) Ductal cancers of the pancreas frequently express markers of gastrointestinal epithelial cells Gastroenterology, 98, pp. 1655-65.
81. Wagner, M and Greten, FR and Weber, CK and Koschnick, S and Mattfeldt, T and Deppert, W and (2001) A murine tumor progression model for pancreatic cancer recapitulating the genetic alterations of the human disease Genes Dev, 15, pp. 286-93.
82. Song, SY and Gannon, M and Washington, MK and Scoggins, CR and Meszoely, IM and Goldenring, JR and (1999) Expansion of Pdx-1-expressing pancreatic epithelium and islet neogenesis in transgenic mice overexpressing transforming growth factor Gastroenterology, 117, pp. 1416-26.
83. Miyamoto, Y and Maitra, A and Ghosh, B and Zechner, U and Argani, P and Iacobuzio-Donahue, CA and (2003) Notch mediates TGFα-induced changes in epithelial differentiation during pancreatic tumorigenesis Cancer Cell, 3, pp. 565-76.
84. Heiser, PW and Hebrok, M. (2004) Development and cancer. Lessons learned in the pancreas Cell Cycle, 3, pp. 270-2.
85. Kim, SK and Hebrok, M. (2001) Intercellular signals regulating pancreas development and function Genes Dev, 15, pp. 111-27.
86. Thayer, SP and Pasca di Maliano, M and Heiser, PW and Nielsen, CM and Roberts, DJ and Lauwers, GY and (2003) Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis Nature, 425, pp. 851-6.
87. Berman, DM and Karhadkar, SS and Maitra, A and Montes De Oca, R and Gerstenblith, MR and Briggs, K and (2003) Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours Nature, 425, pp. 846-51.
88. Means, AL and Leach, SD. (2001) Lineage commitment and cellular differentiation in exocrine pancreas Pancreatology, 1, pp. 587-96.
89. Hruban, RH and Wilentz, RE and Kern, SE. (2000) Genetic progression in the pancreatic ducts Am J Pathol, 156, pp. 1821-5.
90. Hruban, RH and Adsay, NV and Albores-Saavedra, J and Compton, C and Garrett, ES and Goodman, SN and (2001) Pancreatic intraepithelial neoplasia. A new nomenclature and classification system for pancreatic duct lesions Am J Surg Pathol, 25, pp. 579-86.
91. New Nomenclature for Classification of Duct Lesions in the Pancreas. Johns Hopkins Pancreas Cancer Web, 1999 Johns Hopkins University. http://pathology.jhu.edu/n.web?EP=N&FL=PANCREAS_PANIN [accessed 3 April 2005].
92. Luttges, J and Schlehe, B and Menke, MA and Vogel, I and Henne-Bruns, D and Kloppel, G. (1999) The K-ras mutation pattern in pancreatic ductal adenocarcinoma usually is identical to that in associated normal, hyperplastic, and metaplastic ductal epithelium Cancer, 85, pp. 1703-10.
93. Moskaluk, CA and Hruban, RH and Kern, SE. (1997) p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma Cancer Res, 57, pp. 2140-3.
94. Wilentz, RE and Iacobuzio-Donahue, CA and Argani, P and McCarthy, DM and Parsons, JL and Yeo, CJ and (2000) Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: Evidence that DPC4 inactivation occurs late in neoplastic progression Cancer Res, 60, pp. 2002-6.
95. Goggins, M and Hruban, RH and Kern, SE. (2000) BRCA2 is inactivated late in the development ofpancreatic intraepithelial neoplasia Am J Pathol, 156, pp. 1767-71.
96. DiGiuseppe, JA and Hruban, RH and Goodman, SN and Polak, M and van den Berg, FM and Allison, DC and (1994) Overexpression of p53 protein in adenocarcinoma of the pancreas Am J Clin Pathol, 101, pp. 684-8.
97. Wilentz, RE and Hruban, RH. (1998) Pathology of cancer of the pancreas Surg Oncol Clin North Am, 7, pp. 43-65.
98. Wilentz, RE and Albores-Saavedra, J and Zahurak, M and Talamini, MA and Yeo, CJ and Cameron, JL and (1999) Pathologic examination accurately predicts prognosis in mucinous cystic neoplasms of the pancreas Am J Surg Pathol, 23, pp. 1320-7.
99. SohnTA, YeoCJ, CameronJL, HrubanRH, FukushimaN, CampbellKA, Intraductal papillary mucinous neoplasms of the pancreas: An updated experience Ann Surg 2004;239:788-97; discussion 797-9.
100. SohnTA, YeoCJ, CameronJL, Iacobuzio-DonahueCA, HrubanRH, LillemoeKD. Intraductal papillary mucinous neoplasms of the pancreas: An increasingly recognized clinicopathologic entityAnn Surg 2001;234:313-21; discussion 321-2.
101. Adsay, NV and Merati, K and Basturk, O and Iacobuzio-Donahue, C and Levi, E and Cheng, JD and (2004) Pathologically and biologically distinct types of epithelium in intraductal papillary mucinous neoplasms: Delineation of an "intestinal" pathway of carcinogenesis in the pancreas Am J Surg Pathol, 28, pp. 839-48.
102. Kloppel, G and Solcia, E and Longnecker, DS and Capella, S and Sobin, LH.(1996) Histological typing of tumours of the exocrine pancreas. In World Health Organization international classification of tumors, 2nd edn. (pp. 11-20). Berlin: Springer.
103. Iacobuzio-Donahue, CA and Ryu, B and Hruban, RH and Kern, SE. (2002) Exploring the host desmoplastic response to pancreatic carcinoma: Gene expression of stromal and neoplastic cells at the site of primary invasion Am J Pathol, 160, pp. 91-9.
104. Yeo, CJ and Sohn, TA and Cameron, JL and Hruban, RH and Lillemoe, KD and Pitt, HA. (1998) Periampullary adenocarcinoma: Analysis of 5-year survivors Ann Surg, 227, pp. 821-31.
105. Exocrine pancreas. In: American Joint Committee on Cancer: AJCC Cancer Staging Manual, 6th edn New York: Springer, 2002:157-64.
106. Berthelemy, P and Bouisson, M and Escourrou, J and Vaysse, N and Rumeau, JL and Pradayrol, L. (1995) Identification of K-ras mutations in pancreatic juice in the early diagnosis of pancreatic cancer Ann Intern Med, 123, pp. 188-91.
107. Caldas, C and Hahn, SA and Hruban, RH and Redston, MS and Yeo, CJ and Kern, SE. (1994) Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia Cancer Res, 54, pp. 3568-73.
108. Lu, X and Xu, T and Qian, J and Wen, X and Wu, D. (2002) Detecting K-ras and p53 gene mutation from stool and pancreatic juice for diagnosis of early pancreatic cancer Chin Med J (Engl), 115, pp. 1632-6.
109. Gronborg, M and Bunkenborg, J and Kristiansen, TZ and Jensen, ON and Yeo, CJ and Hruban, RH and (2004) Comprehensive proteomic analysis of human pancreatic juice J Proteome Res, 3, pp. 1042-55.